IQVIA Holdings Inc
$ 164.88
1.58%
24 Feb - close price
- Market Cap 28,079,065,000 USD
- Current Price $ 164.88
- High / Low $ 166.43 / 162.03
- Stock P/E 20.71
- Book Value 38.34
- EPS 7.96
- Next Earning Report 2026-04-23
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.21 %
- 52 Week High 247.05
- 52 Week Low 134.65
About
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Analyst Target Price
$236.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-10-30 | 2025-07-22 | 2025-05-06 | 2025-02-06 | 2024-10-31 | 2024-07-22 | 2024-05-02 | 2024-02-14 | 2023-11-01 | 2023-08-01 | 2023-04-27 |
| Reported EPS | 3.42 | 3 | 1.54 | 2.7 | 2.42 | 1.55 | 2.64 | 2.54 | 2.84 | 2.49 | 2.43 | 2.45 |
| Estimated EPS | 3.4 | 2.97 | 1.73 | 2.63 | 2.09 | 1.92 | 2.57 | 2.48 | 2.82 | 2.44 | 2.37 | 2.41 |
| Surprise | 0.02 | 0.03 | -0.19 | 0.07 | 0.33 | -0.37 | 0.07 | 0.06 | 0.02 | 0.05 | 0.06 | 0.04 |
| Surprise Percentage | 0.5882% | 1.0101% | -10.9827% | 2.6616% | 15.7895% | -19.2708% | 2.7237% | 2.4194% | 0.7092% | 2.0492% | 2.5316% | 1.6598% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-23 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.95 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IQV
2026-02-24 20:21:34
IQVIA Holdings Inc. (IQV) is considered one of the top life sciences stocks by hedge funds, with Truist Financial reiterating a Buy rating and a price target suggesting significant upside despite a downward revision due to AI-related uncertainties. While TD Cowen maintains a Hold rating, acknowledging long-term AI risks, IQVIA provides comprehensive clinical research and healthcare analytics services globally. The article also suggests that other AI stocks might offer greater upside potential with less risk.
2026-02-24 19:50:34
Despite AI-linked threats and recent price target revisions, IQVIA Holdings Inc. (IQV) is considered one of the top life sciences stocks to buy by hedge funds. Truist Financial reiterated a Buy rating with a significant upside, while TD Cowen maintained a Hold rating, acknowledging AI's long-term risks but uncertain immediate impact on Clinical Research Organizations. IQVIA provides extensive clinical research services, advanced analytics, and commercial solutions to the healthcare and life sciences sectors.
2026-02-24 19:50:27
IQVIA Holdings Inc. (IQV) is identified as a top life sciences stock with impressive upside potential despite AI-related uncertainties. While Truist Financial reiterated a Buy rating with a revised price target offering over 65% upside, TD Cowen maintained a Hold rating, acknowledging potential long-term AI risks but uncertain near-term impact. The company provides clinical research services and advanced analytics to healthcare and life sciences sectors.
2026-02-24 19:50:21
IQVIA Holdings Inc. (IQV) is highlighted as one of the top life sciences stocks according to hedge funds. Truist Financial reiterated a Buy rating with a target of $274, suggesting over 65% upside, despite adjusting its model due to AI-related uncertainties and re-segmentation. TD Cowen maintained a Hold rating, lowering its price target due to potential long-term AI risks, though the immediate impact on CROs is deemed uncertain.
2026-02-24 14:33:00
Despite potential AI-linked threats, IQVIA Holdings Inc. (IQV) is considered one of the top 10 life sciences stocks by hedge funds, offering significant upside potential. Truist Financial reiterated a Buy rating with a revised price target of $274, while TD Cowen maintained a Hold rating, adjusting its price target to $174. The company provides clinical research services, advanced analytics, and market intelligence globally, navigating both short-term AI uncertainties and long-term risks.
2026-02-24 13:53:26
IQVIA Holdings, Inc. has seen a revision in its stock evaluation due to challenging market conditions, resulting in a year-long decline and underperformance against the S&P 500. Technical indicators are mixed but lean bearish overall, with significant drops in stock return over the past month and year-to-date. The company's stock is currently priced at $162.31, down from $165.62, reflecting its struggles in the current market environment.
